Inhibitors of MEK

Details Inhibitors of MEK Inhibitors of MEK

2010-09-10

2011-11-22

Saeed, Kamal (Department: 1622)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S266100, C514S311000, C544S235000, C544S283000, C546S171000

Reexamination Certificate

active

08063049

ABSTRACT:
This invention concerns to N-(2-aylamino)aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.

REFERENCES:
patent: 5861510 (1999-01-01), Piscopio et al.
patent: 5863949 (1999-01-01), Robinson et al.
patent: 0606046 (1994-07-01), None
patent: 0679641 (1995-11-01), None
patent: 0780386 (1997-06-01), None
patent: 97304971.1 (1997-07-01), None
patent: 99302232.1 (1999-03-01), None
patent: 0931788 (1999-07-01), None
patent: 99308617.2 (1999-10-01), None
patent: WO 90-05719 (1990-05-01), None
patent: WO 96-27583 (1996-03-01), None
patent: WO 96-33172 (1996-10-01), None
patent: WO 98-03516 (1998-01-01), None
patent: WO 98-07697 (1998-02-01), None
patent: WO 98-30566 (1998-07-01), None
patent: WO 98-33768 (1998-08-01), None
patent: WO 98-34915 (1998-08-01), None
patent: WO 98-34918 (1998-08-01), None
patent: WO 99-07675 (1999-02-01), None
patent: WO 99-29667 (1999-06-01), None
patent: WO 99-32889 (1999-10-01), None
patent: WO 99-52910 (1999-10-01), None
patent: WO 2000-74681 (2000-12-01), None
patent: WO 2004-031174 (2004-04-01), None
patent: WO 2004-083167 (2004-09-01), None
patent: WO 2005-051302 (2005-06-01), None
patent: WO 2005-051906 (2005-06-01), None
U.S. Appl. No. 60/148,464, filed Aug. 12, 1999.
Ahn et al., “Transformation of Mammalian Cells by Constitutively Active MAP Kinase Kinase,” Science 265;966-970 (1994).
Li, C. et al., “Cyclooxygenase-2 Inhibitors. Synthesis and Pharmacological Activities of 5-Methanesulfonamido-1-indanone Derivatives,” J. Med. Chem. 38:4897-4905 (1995).
PCT/US08/051518 Search Report dated May 21, 2008.
Fleischer et al., “Improved oral drug delivery: solubility limitations overcome by the use of prodrugs,” Adv. Drug Del. Rev. 19:115-130 (1996).
Robinson et al., “Discovery of the Hemifumarate and (α-L-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group,” J. Med. Chem. 39:10-18 (1996).
Vippagunta et al., Crystalline solids, 2001, Advanced Drug Delivery Reviews, 48, pp. 3 and 18.
Wolff et al., Burger's Medicinal Chemistry and Drug Discovery, 1994, Wiley-Interscience, Fifth Edition, vol. I: Principles and Practice, pp. 975-977.
Kwon et al., Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists, 2001, http://www.myilibrary.com/Browse/open.asp?ID=4284&loc=1, Retrieved from the Internet Jun. 16, 2008, p. 213.
Metabolomics [online], Retrieved from the Internet Jun. 16, 2008, URL: http://www.en.wikipedia.org/wiki/Metabolomics, p. 1.
Lala et al., Role of nitric oxide in tumor progression: Lessons from experimental tumors, Cancer and Metastasis Reviews (1998), 17, 91-106.
Golub et al., Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, Science (1999), vol. 286, 531-537.

Affiliated with

Also associated with

Rating

Inhibitors of MEK does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of MEK, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of MEK will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4291097